Sponsor pipeline

Valent Technologies, LLC clinical trial pipeline

Get alerts when Valent Technologies, LLC's trials change

1 active trials 0 recruiting 1 disease areas 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-07-31
Primary completion pushed: 2026-06 → 2026-12
Completion pushed: 2026-06 → 2026-12
NCT04337177 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of… · Phase 1

Active trials by phase

Phase 1
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1
NCT04337177 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of… Solid Tumors Active, Not Recruiting 2026-07-30

Disease areas by active trials

Sarcoma (1)

Get alerts when Valent Technologies, LLC's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free